Johnson & Johnson's cadazolid, for the treatment of pediatric patients with Clostridium difficile infection, has been granted orphan drug status by the FDA.
FDA gives orphan status to J&J's pediatric drug for C. diff infection
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.